In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Zepbound is a medicine you can obtain only by prescription, and it's typically used to address obesity and other ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...